Recent 8-K filings for BVS

• June 4, 2026, 7:54 AM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×2

  Bioventus stockholders elect all 12 director nominees and ratify Grant Thornton as auditor at 2026 annual meeting

  All 12 director nominees elected; votes-for ranged from 61.7M (Sutter) to 68.5M (Dhankhar).

• May 21, 2026, 4:58 PM ET regulatory materiality 0.30 neutral item 7.01

  Bioventus Exogen device reclassified by FDA, CMS updates reimbursement rates; company reiterates 2026 guidance

  FDA reclassified non-invasive bone growth stimulators, including Bioventus' Exogen Ultrasound Bone Healing System, from Class III to Class II on April 16, 2026.

• May 6, 2026, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  Bioventus Q1 revenue up 7% to $132.1M; GAAP EPS $0.04, raises FY26 EPS and CFO guidance

  Revenue $132.1M (+7% YoY); GAAP EPS $0.04 vs -$0.04; Non-GAAP EPS $0.15 vs $0.08 (+88%).

• March 5, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Bioventus Q4 GAAP EPS $0.21, revenue $157.9M; guides FY2026 sales $600-610M

  Q4 revenue $157.9M (+2.8% reported, +10.0% organic); GAAP EPS $0.21 (vs $0.00); non-GAAP EPS $0.24; Adj. EBITDA $36.7M (+30%).

• November 17, 2025, 6:59 PM ET leadership materiality 0.40 neutral item 5.02

  Bioventus appoints Ajay Dhankhar to board as Smith & Nephew designee

  Appointment effective November 14, 2025; Dhankhar serves as Class II director until 2026 annual meeting.

• November 4, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Bioventus Q3 GAAP EPS $0.05 vs -$0.08 YoY; organic revenue +8% to $138.7M

  GAAP net income $3.2M vs $5.2M loss; diluted EPS $0.05 improved from -$0.08 YoY.

• August 6, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Bioventus Q2 organic revenue up 6.2%; EPS $0.11 vs loss; reaffirms FY2025 guidance

  Revenue $147.7M (-2.4% reported); organic revenue +6.2%, driven by double-digit growth in Surgical Solutions and Restorative Therapies.

• August 4, 2025, 7:59 PM ET debt materiality 0.50 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings

  Bioventus enters $400M credit facility to refinance existing debt

  $100M revolving credit facility and $300M term loan A facility, maturing July 31, 2030.

• July 31, 2025, 7:59 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  Bioventus receives FDA 510(k) clearances for TalisMann and StimTrial PNS products

  FDA granted 510(k) clearance for TalisMann PNS system with integrated pulse generator for deeper/larger nerves.

• June 4, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Bioventus shareholders elect all six director nominees, ratify Grant Thornton as auditor for FY2025

  All six Class I director nominees elected with 58M to 64.9M votes; broker non-votes 8.59M each.

• May 6, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Bioventus Q1 revenue $123.9M, organic +5%; Non-GAAP EPS $0.08, up 33% YoY, guidance reaffirmed

  Q1 revenue $123.9M, reported -4.3% but organic +5.0%; GAAP net loss $0.04/share vs $0.08 prior.

• March 11, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Bioventus Q4 revenue $153.6M (+13.5%); FY2025 guidance implies 6-8% organic growth

  Q4 net loss from cont ops $0.3M vs ($7.7M) prior year; adj EBITDA $28.3M (+28.3%).

• January 3, 2025, 6:59 PM ET M&A materiality 0.70 positive item 2.01item 8.01item 9.01

  Bioventus completes divestiture of Advanced Rehab business to Accelmed for $25M cash plus $20M earn-out

  Closed sale of Advanced Rehabilitation business to Accelmed Partners on Dec 31, 2024.

• November 5, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Bioventus Q3 revenue up 15% to $139M; raises FY2024 guidance midpoint

  Q3 revenue $139.0M (+15.0% YoY); net loss improved to $5.4M from $8.8M; Adjusted EBITDA $23.6M (+8.4%).

• October 4, 2024, 7:59 PM ET M&A materiality 0.70 positive item 1.01item 8.01item 9.01

  Bioventus divests Advanced Rehabilitation business to Accelmed for up to $45M

  Total cash consideration of $45M: $25M at close plus up to $20M in earn-outs.

• August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Bioventus Q2 revenue up 10.3% (organic +13.9%); raises FY2024 guidance

  Revenue $151.2M (+10.3% YoY); Pain Treatments +17.2%, Surgical Solutions +18.6% US.

• July 19, 2024, 7:59 PM ET litigation materiality 0.65 neutral item 8.01

  Bioventus settles securities class action for $15.25M; insurers to cover ~$6.5M

  Settlement amount $15.25M plus interest, subject to court approval; all claims against Bioventus and defendants dismissed.

• June 21, 2024, 7:59 PM ET other material materiality 0.30 neutral item 1.01item 9.01

  Bioventus amends stockholders agreement to phase out classified board structure

  Amendment to Stockholders Agreement moves to annual director elections after 2024 annual meeting.

• June 17, 2024, 7:59 PM ET other material materiality 0.35 neutral item 3.03item 5.03item 5.07item 9.01

  Bioventus stockholders approve board declassification, annual director elections by 2026

  Declassification Charter Amendment approved: 61,439,110 for, 135,200 against, 22,572 abstain.

• May 7, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Bioventus Q1 revenue $129.5M (+8.7% YoY), guides FY24 higher

  Net loss from continuing ops $6.0M vs $100.0M prior year; diluted loss per share $0.07 vs $1.28.

• March 12, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases ×3

  Bioventus Q4 revenue up 7.6% to $135.4M; guides FY2024 sales $520-535M

  Q4 revenue $135.4M (+7.6% reported; +14.3% organic); Pain Treatments grew >20%.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

13 positive 0 negative 8 neutral

source · BVS on sec.gov